Nomura Holdings’s Stoke Therapeutics STOK Stock Holding History

Nomura Holdings’s Portfolio STOK Stock Details STOK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-20,400	Closed	-$1.26M	–	2256
2020 Q4	$1.26M	Buy	+20,400	New	+$935K	﹤0.01%	961

Other funds holding STOK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Nomura Holdings's STOK Position: Q2 2026 in Review

Nomura Holdings sold out of Stoke Therapeutics (STOK) in Q2 2026, closing a stake of 26,891 shares — an estimated $876K sold.

Nomura Holdings first reported a position in STOK in Q3 2025 and held it in 3 quarters. The position peaked at $1.91M in Q3 2025. 197 funds tracked by Wall St. Rank hold STOK as of Q2 2026.

Nomura Holdings reported no remaining Stoke Therapeutics position as of Q2 2026 after selling out during the quarter.
Nomura Holdings sold 26,891 Stoke Therapeutics shares in Q2 2026, an estimated $876K.
Nomura Holdings first reported a position in Stoke Therapeutics in Q3 2025 and held it in 3 quarters.
Nomura Holdings's Stoke Therapeutics position peaked at $1.91M in Q3 2025.
197 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q2 2026.

Based on Nomura Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.